Identification of a specific marker panel for human mesenchymal stem cell-derived small extracellular vesicles
Lei Luo , Zhengsheng Chen , Ji Yuan , Xin Niu , Jiashuo Liu , Chao Gu , Hong Xu , Chuncui Jia , Tao Na , Shufang Meng , Yang Wang , Haiyan Li , Qing Li
Interdisciplinary Medicine ›› 2025, Vol. 3 ›› Issue (6) : e70065
Human mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) have demonstrated significant immunomodulatory and pro-regenerative potentials. However, the lack of specific markers to define MSC-sEVs presents a major challenge for their clinical application. Here, the proteomic datasets of MSC-sEVs from three cell sources were synchronously analyzed, and several surface antigens commonly found on MSCs were selected as candidate markers due to their high abundances in MSC-sEVs. Next, MSC-sEVs from three cell sources (adipose tissue, umbilical cord, and induced pluripotent stem cells) were stained with fluorescein-conjugated antibodies and analyzed by NanoFCM at single-vesicle resolution. The positive rates of CD13, CD29, and CD90 all exceeded 60% across sEVs derived from three MSCs sources, whereas other candidates generally exhibited lower positive rates. The high positive rates of them were further verified in MSC-sEVs purified via other methods. Moreover, high-resolution microscopy, as an orthogonal method, visually validated their high presence in MSC-sEVs. Meanwhile, none of the non-MSC-sEVs showed concurrent positive rates for CD13, CD29, and CD90 exceeding 40%, suggesting that this marker panel (with a positive rate threshold of 50% for all three markers) could specifically distinguish MSC-sEVs from non-MSC-sEVs. Finally, the positive rates of this panel of markers were assessed in sEVs derived from MSCs at successive passages. The results revealed a progressive diminution of the positive rates of CD29 and CD90 in the sEVs secreted by MSCs with successive passages, accompanied by a reduction in the pro-proliferative activity of these sEVs. Taken together, we have identified a specific and quantifiable marker panel for MSC-sEVs characterization, which facilitates the development of standardized assays for defining MSC-sEVs and ultimately accelerates the clinical translation of MSC-sEVs.
identification / marker / mesenchymal stem cells / proteomics / small extracellular vesicles
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
2025 The Author(s). Interdisciplinary Medicine published by Wiley-VCH GmbH on behalf of Nanfang Hospital, Southern Medical University.
/
| 〈 |
|
〉 |